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O B J E C T I V E S The purpose of this study was use molecular imaging targeting coagulation pathway
and inﬂammation to better understand the pathophysiology of silent brain ischemia (SBI) and monitor
the effects of factor XIIa inhibition.
B A C KG ROUND SBI can be observed in patients who undergo invasive vascular procedures. Unlike
acute stroke, the diffuse nature of SBI and its less tangible clinical symptoms make this disease difﬁcult
to diagnose and treat.
METHOD S We induced SBI in mice by intra-arterial injection of ﬂuorescently labeled microbeads or
fractionated clot into the carotid artery. After SBI induction, diffusion-weighted magnetic resonance
imaging was performed to conﬁrm the presence of microinfarcts in asymptomatic mice. Molecular
imaging targeting the downstream factor XIII activity (single-photon emission computed tomography/
computed tomography) at 3 h and myeloperoxidase activity (magnetic resonance imaging) on day 3
after SBI induction were performed, without and with the intravenous administration of a recombinant
selective factor XIIa inhibitor derived from the hematophagous insect Triatoma infestans (rHA-Infestin-4).
Statistical comparisons between 2 groups were evaluated by the Student t test or Mann-Whitney U test.
R E S U L T S In SBI-induced mice, we found abnormal activation of the coagulation cascade (factor XIII
activity) and increased inﬂammation (myeloperoxidase activity) close to where emboli lodge in the brain.
rHA-Infestin-4 administration signiﬁcantly reduced ischemic damage (53% to 85% reduction of infarct
volume, p  0.05) and pathological coagulation (35% to 39% reduction of factor XIII activity, p  0.05)
without increasing hemorrhagic frequency. Myeloperoxidase activity, when normalized to the infarct
volume, did not signiﬁcantly change with rHA-Infestin-4 treatment, suggesting that this treatment does
not further decrease inﬂammation other than that resulting from the reduction in infarct volume.
CONC L U S I O N S Focal intracerebral clotting and inﬂammatory activity are part of the pathophys-
iology underlying SBI. Inhibiting factor XIIa with rHA-Infestin-4 may present a safe and effective
treatment to decrease the morbidity of SBI. (J Am Coll Cardiol Img 2012;5:1127–38) © 2012 by the
American College of Cardiology Foundation
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1128ehavioral changes, neuropsychological defi-
cits, and aggravated vascular dementia can
be observed in patients after cardiovascular
surgery (e.g., coronary bypass surgery, valve
eplacement, carotid endarterectomy) and in pa-
ients undergoing vascular interventions (1). With
he advent of sensitive imaging modalities such as
iffusion-weighted magnetic resonance imaging
MRI), there has been an increasing awareness of
njury to the brain in patients without major symp-
oms. These lesions, called silent brain ischemia
SBI), are thought to be caused by microembolism
rom debris, air, fat, or fragmented thrombi (2,3).
he overall incidence in the general patient popula-
ion is 2% to 3%, with a prevalence increasing with age
f up to 20% in the elderly (3,4). Vascular procedures,
uch as angiography, carotid endarterectomy and
stenting, and heart surgery can increase the
risk for SBI substantially (1,3). The presence
of SBI has also been found to be associated
with dementia and increased risk of stroke
(4). Currently, no effective therapy exists for
treating this condition.
In this work, we reasoned that coagula-
tion factor XII (FXII) can serve as a
potential therapeutic target in SBI. FXII is
a serine protease that initiates the intrinsic
coagulation cascade by activation of fac-
tors XI to XIa (5) and also has immuno-
modulatory functions (6). It binds an Fc
receptor on monocytes, increases the re-
lease of interleukin-1 and -6 from mono-
cytes and macrophages and stimulates
neutrophils (7–9). FXII also activates
chemerin, a chemoattractant that binds a
G protein–coupled receptor on dendritic
ells and macrophages, directing an immune re-
ponse to the site of injury (10). Additionally, FXII
ctivates prekallikrein and thus bradykinin forma-
ion, which in turn is a potent inflammatory medi-
tor that induces vasodilation and vascular leakage
11). FXII-deficient mice have decreased plasma
radykinin levels, suggesting that FXII may ame-
iorate a potentially harmful inflammatory response
hat can cause further damage (12,13). It has been
uggested that FXII improves the strength and size
f a developing thrombus (11). Interestingly, defi-
iency or inhibition of FXII protects against arterial
hrombus formation and reduces cerebral injury in
ouse models of stroke without increasing the risk
f bleeding (14,15). In humans, hereditary defi-




eleeding diathesis (16). That a FXII-driven path-ay is required for pathological thrombus forma-
ion but is not involved in hemostasis suggests that
XII inhibition could be a promising and safe
herapeutic strategy (17,18) for SBI.
Infestins are a class of serine protease inhibitors
erived from the midgut of the hematophagous
nsect, Triatoma infestans, a major vector for the
arasite Trypanosoma cruzi, known to cause Chagas
isease (19). The insect uses these inhibitors to
revent coagulation of ingested blood. The Infestin
ene encodes 4 domains that express proteins in-
ibiting different factors in the coagulation pathway
19), including Infestin-4, a strong inhibitor of
ctivated coagulation factor XII (FXIIa). In this
tudy, we found that rHA-Infestin-4 (recombinant
nfestin-4, fused to human albumin for prolonga-
ion of blood half-life) decreased the amount of
schemic injury in both a thromboembolic and a
icrobead embolic model that mimics SBI caused
y other materials such as air and fat. We used 2
argeted molecular imaging approaches to examine
reatment effects on the coagulation cascade by
maging activity of the downstream clotting factor
IIIa and to study brain inflammation by MRI of
yeloperoxidase (MPO) activity. We found that in
urine SBI, microembolism caused clotting and
nflammation in the brain and that rHA-Infestin-4
educed microinfarctions via anticoagulatory effects
ithout changing the inflammatory response.
M E T H O D S
Mice. All experiments were performed in adult
Balb/c mice obtained from Charles River Labora-
tories, Inc. (Wilmington, Massachusetts). Thirty-
six mice were used to optimize the animal model
with respect to surgical access and the type and
amount of injected materials. The institutional
review board at Massachusetts General Hospital
approved all animal experiments. Mice were anes-
thetized in an isoflurane chamber with 2% isoflu-
rane by inhalation with 2 l/min of supplemental
oxygen and transferred to a warm heating pad in a
supine position while under isoflurane.
Most likely, SBI in patients is caused by a shower
of minuscule emboli that lodge in the small vessels
in the brain and result in diffuse ischemic injury,
whereas large-scale blood flow is not interrupted.
Therefore, to leave the internal carotid artery intact,
we chose to retrogradely inject embolic material
into the external carotid artery. Thromboemboli
and microbeads were injected 1-sided through theA B B R E V I A T I O N S
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1129artery while the common carotid artery was tempo-
rarily occluded. This forced the emboli into the
arterial system of the brain without compromising
perfusion. Ethicon 8-0 mononylon sutures (John-
son & Johnson, Brussels, Belgium) were used for all
arterial ligations. A temporary ligation was made on
the common and internal carotid arteries to stop the
blood flow during catheter placement. The distal
suture around the external carotid artery was per-
manently tied off, and a second suture was placed
around the artery to secure the catheter. The
external carotid artery was opened 5 mm distal to
the carotid bifurcation. We then inserted a modi-
fied intramedic polyethylene PE10 catheter (inner
diameters of 0.28 and 0.61 mm, Becton, Dickinson
and Company, Sparks, Maryland) retrogradely into
the external carotid artery, with the tip of the
catheter facing the bifurcation (Fig. 1). The ligation
on the internal carotid artery was then released,
allowing for flow of injected material into the
internal carotid artery. Flashback of arterial blood
into the catheter was observed, and then either
microbeads or thromboemboli were injected. In a
control group, we only ligated the external carotid
artery, which did not lead to ischemic injury of the
brain. After injection of emboli, the catheter was
removed, and the external carotid artery was ligated
to stop bleeding. The ligatures at the internal and
common carotid arteries were removed to re-
establish arterial flow, and the wound was closed
with 7-0 nylon sutures.
Fluorescent microbeads. After optimization experi-
ments, we found that intracarotid injection of 500
Figure 1. Model of SBI
(A) Fluorescent microbeads and fractionated ﬂuorescent thromboem
external carotid artery (ECA). During injection, the common carotid
artery (ICA). (C) Ex vivo ﬂuorescence images of the brain surface aft
sion-weighted magnetic resonance imaging was done 4 h after em
Multiple small lesions (arrows) are revealed by diffusion-weighted i
areas conﬁrmed restricted diffusion, which is characteristic of acute infamicrobeads of 43-m diameter resulted in repro-
ducible, clinically silent microlesions. A syringe
loaded with 500 Fluoresbrite Plain YG 45 Micro-
spheres (excitation/emission: 441 nm/486 nm,
Polysciences, Inc., Warrington, Pennsylvania) was
attached to the catheter to inject the beads (Fig. 1).
Fluorescent thromboemboli. Fresh mouse blood
(500 l) was withdrawn from donor mice via
ardiac puncture and immediately added to sodium
itrate solution for initial anticoagulation (final
oncentration, 0.32%). After centrifugation at
,500 rpm for 10 min to remove cells, 20 mol
aCl2 and 10 units of high-activity human throm-
in were added to the plasma to induce clotting
molecular weight, 37,000, 100 U/ml, specific ac-
ivity 2,800 NIH U/mg protein, Calbiochem,
MD Chemicals, Inc., Darmstadt, Germany). To
abel the thromboemboli, 2 nmol of Genhance 680
Perkin Elmer, Massachusetts) was added. The
aterial was stored at 4°C for up to 72 h. Before
se, the clot was washed with normal saline solution
nd treated with a tissue homogenizer to fractionate
he clot into small particles 10 m in diameter
(Fig. 1). Optimization experiments determined that
a volume of 10 l of this preparation did not cause
overt neurological deficits.
These emboli sizes were chosen to better account
for the variability of different types of injury that
may occur in the clinical setting. The human
middle cerebral artery is 4 mm in diameter, with
large emboli considered to be those 2 mm in size.
Mouse middle cerebral artery is 80 microns in
diameter. Therefore, we chose 2 types of emboli
li before injection. (B) Surgical approach with catheter retrogradely in
ry (CCA) was temporarily ligated to force the embolic material into t
jection of either microbeads or thromboemboli; scale bar indicates 2
sm and shows hallmarks of silent brain ischemia (SBI), similar to what
ing (DWI). A decrease in the apparent diffusion coefﬁcient (ADC) in tbo serted into the
arte he internal carotid
er in 00 m. (D) Diffu-



































































J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 5 , N O . 1 1 , 2 0 1 2
N O V E M B E R 2 0 1 2 : 1 1 2 7 – 3 8
Chen et al.
Factor XIIa Inhibition Attenuates SBI
1130that can be considered small (10 microns) and
relatively large (43 microns, just 50% of the
iameter of mouse middle cerebral artery).
Stroke assessment. After recovery from anesthesia,
mice were assessed for signs of stroke using the
Benderson scale (20) after SBI induction. We also
observed the animals for dyskinesia, lethargy, grip,
limb weakness, eyelid droop, gait disturbance, cir-
cling, and rolling. Observation of any of these
symptoms was considered to be an indicator of
stroke, whereas lack of these symptoms and a
Benderson score of 0 (normal) indicated that no
overt stroke had occurred, consistent with the
possibility of SBI. If no stroke symptoms were
present, the mice were used for this study; other-
wise, they were excluded. A total of 4 mice were
excluded after thromboembolism and 7 mice after
microbead injection.
Study groups. After optimization of the animal
odel, we proceeded to study 4 cohorts (n  5 to
per group): mice with induction of SBI by
hromboemboli or microbeads (untreated controls),
nd 2 additional groups in which mice were treated
ith rHA-Infestin-4 (CSL Behring GmbH) at a
ose of 200 mg/kg via intravenous tail vein injec-
ion. The mice received their first injection imme-
iately after SBI induction. Single-photon emission
omputed tomography (SPECT)/computed to-
ography (CT) of FXIII activity was done 3 h after
BI. The cohorts that were imaged 3 days after SBI
y MRI received daily injections until and including
ay 3 after injury. 2,3,5-Triphenyltetrazolium chlo-
ide (TTC) staining was assessed 3 days after SBI to
easure the microinfarct burden.
MRI to assess infarct volume and MPO activity. MRI
was performed using a Bruker (Billerica, Massachu-
setts) 4.7-T scanner with a RARE T1-weighted
(T1w) sequence (repetition time [TR] 1,500 ms;
echo time [TE] 8 ms; averages 8; matrix 192 192
 22; voxel size 0.133  0.13 mm  0.5 mm); and
RARE T2-weighted (T2w) sequence with the
ame geometry (TR 5,622 ms; TE 20 ms; averages
). To evaluate the model, we also used diffusion-
eighted imaging after SBI induction. An echo
lanar imaging diffusion-weighted sequence with 6
iffusion directions was used (TR 4,800 ms; TE 32
s; matrix 128  128  22; voxel size 0.195 
.195  0.5 mm).
MPO is an abundant enzyme secreted by many
nflammatory myeloid cells such as neutrophils,
y-6Chigh monocytes, subsets of activated macro-
hages, and microglia during inflammation and thus
s a suitable imaging biomarker for the local inflam- oatory response. Mice were scanned before and 90
in after intravenous administration of 0.3 mmol/kg
f MPO-gadolinium contrast agent (MPO-Gd
bis-5-hydroxytryptamidediethylenetriaminepenta-
cetatic acid-gadolinium]) (21–23) 3 days after SBI
nduction. MPO-Gd is a gadolinium-encaging chela-
or (diethylenetriaminepentaacetate) derivatized with
serotonin moieties and can react with other
PO-Gd molecules to form oligomers in tissue with
igh MPO activity, but remain as single molecules in
he absence of MPO activity (21,24). MPO-Gd
auses highly MPO-specific tissue enhancement
22,23). After imaging, mice were killed, perfused
ith normal saline solution, and the brains were
arvested and sliced for fluorescence imaging on a
esoscopic fluorescent imager (OV-100, Olympus
orp., Center Valley, Pennsylvania) to verify that
mboli were present.
Amira (Visage Imaging, San Diego, California)
nd Matlab (MathWorks, Natick, Massachusetts)
oftware was used for data analysis. T2w images
ere segmented by region-based thresholding for
olume computation and 3-dimensional visualiza-
ion of lesions. Regions of interest were identified
n each image slice of the 90-min post-injection
1w scans. The brain ventricles were excluded by
anual segmentation of T2w images before auto-
ated segmentation of MPO-Gd positive areas on
1w scans. MPO-Gd–positive voxels were quanti-
ated using a Matlab procedure that counted voxels
ith a signal intensity that was 3 SDs above the
verage signal in normal brain tissue. To determine
hether Infestin has additional effects on inflamma-
ion, the MPO-Gd–positive volume was normalized
o the T2 volume to account for change in infarct size.
n addition, we quantified the contrast-to-noise ratio,
hich reflects the degree of inflammation in tissue
22,23). This approach was validated previously, in-
luding imaging in MPO/ mice (22).
SPECT-CT to assess clotting cascade activation. Be-
cause cross-linking of fibrin by FXIII is considered
the final step in the formation of a clot, it is a useful
measure of overall clotting activity. We performed
in vivo SPECT-CT imaging using the FXIII-
specific molecular probe FXIII-indium (25,26) dur-
ing the acute stage after SBI induction. This imag-
ing agent consists of an indium 111–labeled peptide
that is recognized by FXIII as specific substrate and
is then incorporated into the forming clot. Previous
work carefully characterized the specificity of
the imaging agent using a scrambled peptide se-
quence (27) and FXIII/ mice (26). Four groups
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1131before injection of approximately 1 mCi of a factor
XIII substrate peptide labeled with indium 111
(actual amount injected was 731 to 1,273 Ci).
PECT-CT was performed using the Gamma
edica-Ideas (Northridge, California) XSPECT
mall animal imaging system. We used a cone beam
50 kVp, 500 mA) x-ray tube with a solid-state
MOS detector over 256 projections. These pro-
ections were reconstructed using the modified
eldkamp reconstruction algorithm. The SPECT
can used dual gamma cameras with 1-mm medium
nergy pinhole collimators through 64 projections
32 projections from each camera) at 90 s/projec-
ion. The SPECT images were reconstructed using
he ordered subsets expectation maximization algo-
ithm and fused to the CT images for accurate
natomic colocalization of molecular information.
Animals were killed immediately after SPECT-
T imaging. The brain was excised and tissue ana-
yzed with a Wallac Wizard 1480 gamma well counter
Perkin-Elmer, Waltham, MA). Afterward, the brain
as sliced into 2-mm thick sections and imaged by
uorescence reflectance imaging as described in the
ollowing to verify the presence of fluorescent emboli.
fterward, the tissue slices were placed on phosphor-
mager plates overnight for autoradiography and ana-
yzed on a Molecular Dynamics Typhoon phosphor
mager plate reader (Sunnyvale, California).
For SPECT-CT data analysis, the entire brain
nd skeletal muscle were manually segmented from
he CT images using Amira software to calculate
he target-to-background ratio, with muscle activity
erving as background. Data were normalized for
he mass of the brain and the injected dose of each
nimal. Autoradiography and gamma counting data
ere decay corrected to the time of killing of the
ice. Three-dimensional visualizations of the
PECT-CT data were rendered using Osirix soft-
are (Geneva, Switzerland).
Ex vivo imaging and pathology. After the mice were
illed, the brains were cut into 2-mm thick coronal
ections using a mouse brain slicer (Zivic Instru-
ents, Pittsburgh, Pennsylvania) and imaged with
n OV-100 small animal imaging system (Olympus
orp.), a hybrid of a planar reflectance fluorescence
maging system and a high-power microscope. The
rain sections were imaged using the green fluores-
ent protein channel (excitation, 400 nm; emission,
08 nm) for the microbeads and the near-infrared
hannel for the fluorescent thromboemboli (excita-
ion 680 nm) with as high as 16 magnification.
hite-light images were also acquired to assess
otential hemorrhage caused by injury. bTo assess microinfarct burden 3 days after SBI,
rain slices were produced and placed in a 1% TTC
n phosphate-buffered saline solution for 30 min at
7° C. The brain sections were then washed 3 times
ith phosphate-buffered saline solution for 1 min
ach and then imaged using a digital camera
Olympus FE-280) to assess TTC staining. Viable
rain tissue stained red with TTC, whereas in-
arcted regions did not stain.
Histology. For further histological analysis, slices of
rain tissue were embedded in O.C.T. compound
Sakura Finetek, Torrance, California), and serial
-m frozen sections were cut. The avidin-biotin
peroxidase method was used for immunohisto-
chemistry, and tissue sections were incubated with
factor XIIIA: C-20 (Santa Cruz Biotechnology,
Inc., Santa Cruz, California) followed by a biotin-
ylated anti–goat IgG secondary antibody (Vector
Laboratories, Inc., Burlingame, California). The reac-
tion was visualized with a 3-amino-9-ethylcarbazole
substrate (DakoCytomation, Carpinteria, Califor-
nia), and all sections were counterstained with
Harris hematoxylin solution. The slides were digi-
tized automatically at 400 magnification, and
images were captured using NanoZoomer 2.0-HT
(Hamamatsu Photonics K.K., Shizuoka, Japan).
Statistics. Results are expressed as mean  SEM.
Statistical comparisons of the 2 groups were evalu-
ated by the Student t test or Mann-Whitney U test
(if the variances were significantly different in the 2
groups, assessed by the F test). A value of p  0.05
was considered to indicate statistical significance.
R E S U L T S
Mouse model of SBI. We found that in 5 control
mice, ligation of the external carotid artery and
placement of the catheter but without injection of
thrombogenic material did not cause ischemic in-
jury. When these mice were imaged by SPECT-
CT or MRI, we did not find injury sequelae. Next,
we chose 2 different materials to mimic microem-
bolism, accounting for the heterogeneous nature of
SBI. Fluorescent microbeads 43 m in diameter, as
well as fractionated blood clots that were labeled
with fluorochromes (10 m in size), resulted in
ariable symptoms and degree of tissue damage,
epending on the amount of material injected. In
ptimization experiments, we adjusted the quantity
f embolic material to avoid neurological deficits
hat are the hallmark of stroke, which we frequently
ound if 1,000 microbeads or 30 l of throm-
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1132microbeads and 10 l of thromboembolic material
rarely caused strokelike symptoms, and we chose
these quantities for all further experiments. If stroke
symptoms occurred nevertheless, animals were ex-
cluded from the study.
Both embolic materials were fluorescent; thus,
we could observe how they produced occlusions in
small cerebral vessels (Figs. 1A, 1B, and 1C) and
microinfarctions in the brain. Fluorescent labeling
of emboli also allowed us to locate them in the
target tissue; thus, fluorescence imaging served as
quality control for the procedure in all subsequent
experiments. Most emboli and subsequent mo-
lecular imaging signal was located in the ipsilat-
eral hemisphere; however, some spillover, likely
through anastomoses provided by the circle of
Willis, was observed in the contralateral hemi-
sphere. Diffusion-weighted MRI showed the typi-
cal subtle changes that are described in human
patients with SBI (Fig. 1D).
rHA-Infestin-4 administration reduces tissue damage in
SBI. To assess the amount of brain tissue damage
aused by emboli, we computed the percentage of
he brain that is infarcted for each model from MRI
Figs. 2A and 2B). We found both SBI models
esulted in infarct volumes that were, on average,
4% of the brain volume, which is substantially less
-4 Reduces Injury Quantiﬁed by MRI and TTC on Day 3 After SBI
farct volume by T2-weighted MRI on day 3 after SBI (Mann-Whitney
-triphenyltetrazolium chloride (TTC) staining on day 3 after SBI. Figur
ns as in Figure 1.han the average infarct volume in human stroke
atients, which averages 9% (28). Interestingly,
he microbead model generated slightly larger av-
rage infarct volume compared with the thrombo-
mboli model (3.5  1.3% vs. 1.1  0.4%, p 
.09). To corroborate the imaging data, we also
erformed TTC staining of slices harvested from
ice 3 days after embolization. Both types of
icroembolization produced small infarcts (Figs.
C and 2D) that occupied 5% of the brain by
rea, similar to the volume results from MRI.
gain, we found that injection of microbeads pro-
uced slightly more tissue damage compared with
he thromboemboli (4.9  0.9% vs. 2.1  0.5%,
 0.06).
When mice were treated with rHA-Infestin-4,
ignificantly decreased microinfarction was detected
y MRI for both materials (microbeads model 53%
eduction; thromboemboli model 85%) (Figs. 2A
nd 2B). TTC staining further confirmed these
ndings (microbead model 54% reduction; throm-
oemboli model 66% reduction) (Figs. 2C and 2D).
We found evidence of microhemorrhages in 6 of
mice (75%) injected with microbeads and in 5 of
mice (56%) injected with thromboemboli (Fig. 3).
fter rHA-Infestin-4 administration, the occur-
ence of microhemorrhage did not increase. In fact,
st). Arrows indicate foci of microinfarcts. (C, D) Assessment of
ows bar graphs and representative MRI. Values are mean  SEM.Figure 2. rHA-Infestin
(A, B) Assessment of in U te
tissue damage by 2,3,5 e sh
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1133treatment reduced the occurrence of microhemor-
rhages from 75% to 67% in the bead model and
from 55% to 12% in the clot model (p  NS and
0.07, respectively) (Fig. 3).
rHA-Infestin-4 treatment decreases clotting secondary
to SBI. To assess the effect of rHA-Infestin-4 on
coagulation, we studied the activity of FXIII, which
is downstream from and affected by FXII and
responsible for cross-linking fibrin clots. In mice
with SBI, we found diffuse SPECT signal in the
ipsilateral brain hemisphere, indicating that the
injected microemboli induced intravascular coagu-
lation once they lodged in the brain. The location of
the SPECT signal was corroborated by ex vivo
autoradiography, which also showed that activity
colocalized with microbeads and thromboemboli on
fluorescence reflectance images (Figs. 4 and 5).
There was a significant reduction in the amount
Figure 3. Secondary Hemorrhage Is Not Increased by rHA-Infes
Assessment of secondary hemorrhage on day 3 after injection of m
indicate mice in which hemorrhage was detected (arrows).of FXIII activity after rHA-Infestin-4 administra-tion in SBI caused by both injection of thrombo-
emboli (Fig. 4) and microbeads (Fig. 5). This was
corroborated by ex vivo autoradiography exposure
of brain sections (middle panels of Figs. 4 and 5).
The overall degree of factor XIII activity reduction
is visualized on the 3-dimensional SPECT-CT
images (Figs. 4 and 5, left panels). Immunohisto-
chemical staining for FXIII confirmed in vivo
imaging results (Fig. 6).
rHA-Infestin-4 does not alter MPO activity in the brain
after SBI. To assess MPO activity in vivo, we per-
formed MRI 3 days after SBI using the molecular
imaging agent MPO-Gd. In a cohort of normal
mice, no enhancement was found after injection of
MPO-Gd (data not shown). In mice with SBI, we
found diffuse enhancement after injection of MPO-
Gd, colocalizing with the embolic material on ex
vivo fluorescence images (Figs. 7 and 8). Injection
beads or thromboemboli. One representative brain slice is shown petin-4
icro r mouse. Red framesof microbeads induced more MPO activity com-
of tissue (%IDGT). (D) 5. C
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1134pared with thromboemboli (contrast-to-noise ratio:
microbeads 36  1; thromboemboli 23  2; p 
0.05) and larger lesions (number of MPO-Gd–
positive voxels in the brain: microbeads 3,162 
1,435; thromboemboli 548  207; p  0.05).
In both models, there was a trend toward a
decrease in MPO-Gd–positive volume after rHA-
Infestin-4 treatment. Interestingly, after accounting
for infarct volume, we found that the normalized
MPO-positive volume did not change after treat-
ment (Figs. 7 and 8). The average contrast-to-noise
ratio of MPO-positive lesions was also unchanged
(Figs. 7 and 8).
D I S C U S S I O N
Due to the absence of severe clinical signs and
symptoms, SBI is a complication of medical proce-
dures that is difficult to diagnose and therefore often
overlooked. Increased use of diffusion-weighted MRI
has provided evidence that the incidence of SBI
-4 Reduces Clotting in Thromboemboli-Induced SBI
sglutaminase activity (factor XIIIa) 3 h after application of thromboem
y (CT), autoradiography, and ﬂuorescence reﬂectance imaging (FRI). (B
io (TBR), ex vivo scintillation counting of entire brain (Mann-Whitney
Quantiﬁcation of autoradiography. Values are mean  SEM. *p  0.0increases with age and vascular procedures. There isno clinical treatment available. We used a mouse
model that reflects the heterogeneous pathophysiol-
ogy of SBI by using microthrombi and microbead
embolism to study the sequelae of SBI with respect to
intravascular activation of the coagulation system and
the inflammatory response. Regardless of the material
for the microemboli, in the absence of stroke-like
symptoms, we found activation of the clotting cascade
in the vicinity of the microemboli, measured by
SPECT-CT imaging FXIII activity, a clotting factor
that is involved in the final step of the coagulation
cascade. We further detected increased inflammatory
activity, reported by MPO MRI. Furthermore, we
report that rHA-Infestin-4, a recombinant factor XIIa
inhibitor fused to human albumin for prolongation of
its half-life, significantly reduced both FXIII activity
and the burden of microinfarction. These findings
suggest rHA-Infestin-4 as a potential treatment in
patients with a diagnosis of SBI.
Clinicians frequently encounter neuropsychological
symptoms in patients who underwent major cardio-
li by single-photon emission computed tomography (SPECT)-
fter rHA-Infestin-4 administration. (C) Quantiﬁcation of SPECT tar-
st). Data are shown as the percentage of injected dose per gram
PM  counts per minute; SBI  silent brain ischemia.Figure 4. rHA-Infestin
(A) Assessment of tran bo
computed tomograph ) A
get-to-background rat U tevascular interventions. Because conventional brain im-
as
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1135aging techniques showed no anatomic correlates, these
“subtle” changes in alertness, orientation, mood, and
character were often dismissed as difficulty to adjust to
the hospital environment or advanced age. The advent
of imaging techniques that have very high sensitivity,
such as DWI MRI, has brought to light that an
astounding number of patients have post-procedural
impairment of diffusion in their brains (1,3). Improv-
ing our understanding of SBI biology, we found that
in mice after microembolization, regardless of the
material of the emboli, there is considerable pathol-
ogy, even in the absence of stroke symptoms. Specif-
ically, FXIII activity was increased 3 h after emboli-
zation, indicating increased coagulation at the site
where embolic material lodged. Three days later, these
brain areas showed significant inflammation as a
response to the tissue injury. We speculate that the
arrest of blood flow in the smallest vessels in the brain
after fragmented clot or beads lodged in them caused
secondary clotting and ischemic death of small vol-
umes of brain tissue and in some cases microhemor-
rhages. Secondary intravascular clotting may thus
Figure 5. rHA-Infestin-4 Reduces Clotting in Microbead-Induced
(A) Assessment of transglutaminase activity (factor XIIIa) 3 h after a
administration. (C) Quantiﬁcation of SPECT TBR and ex vivo scintilla
autoradiography. Values are mean  SEM. *p  0.05. Abbreviationsserve as a therapeutic target, as seen in the mousecohorts treated with rHA-Infestin-4. The described
mouse model can be used for future studies of SBI,
especially to test therapeutic approaches to prevent it.
The use of fluorescent embolic material is advanta-
geous because it can serve as a quality control for the
procedure and informs on where the injected materials
lodged, which is otherwise difficult to determine.
Commercially available fluorescent microbeads proved
particularly suitable because the amount of injury can
be standardized due to the homogeneous size of beads
and the ease of dosing.
We characterizedSBI in mice using 2 molecular
imaging approaches that are well positioned to
detect subtle changes early in the course of disease.
MPO activity was imaged by MRI on day 3, when
the inflammatory activity peaks in stroke (23). The
increased MPO activity suggests that a response
occurs that parallels stroke, specifically, the recruit-
ment of innate immune cells to the site of injury. At
this point, it is unclear whether subsequent inflamma-
tion exacerbates ischemia of brain cells and whether it
also could be targeted therapeutically. In the current
cation of microbeads by SPECT-CT, autoradiography, and FRI. (B) Afte
counting of entire brain (Mann-Whitney U test). Values are %IDGT. (
in Figures 1 and 4.SBI
ppli r rHA-Infestin-4
tion D) Quantiﬁcation ofstudy, rHA-Infestin-4 did not change the normalized
on o
noise-ratio; MPO  my
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1136MPO-positive volume after accounting for infarct
size, suggesting that this treatment did not have
additional effects on inflammation other than
from the decrease in infarct size. In addition,
MPO signal on day 3 after SBI was not changed
by treatment. Thus, the MPO-Gd–positive areas
seen on imaging may represent breakthrough
injured areas that escaped rHA-Infestin-4 treat-
Figure 6. Immunohistochemistry for FXIII
Immunohistochemical staining for factor XIII (FXIII) 3 h after inducti
Activity on Day 3 After Thromboemboli-Induced SBI
tivity 3 days after SBI induced by thromboemboli. Yellow arrows ind
mboemboli. MPO-positive volume is normalized to T2-positive volum
eloperoxidase; 2D  2-dimensional; 3D  3-dimensional; other abbreviament. As such, these areas did not demonstrate
any change in MPO activity.
As early as 3 h after induction of injury in our
murine models, there was significant SPECT
signal, indicating heightened FXIII activity.
Given the lack of overt symptoms in SBI, recom-
binant tissue plasminogen activator is likely not
suitable for SBI. Even in stroke, patients with
f silent brain ischemia. Bar indicates 50 m.
e MPO-positive lesions; black arrows indicate the ventricle. FRI
alues are mean  SEM. AU  arbitrary units; CNR  contrast-to-Figure 7. MRI of MPO
Assessment of MPO ac icat








to igures 2, 4, and 7.
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1137mild symptoms are not treated with thrombolytic
therapy due to the substantial risk of hemorrhagic
complications (29). Conversely, similar to previ-
ous studies on stroke (14,17), FXII inhibition did
not increase frequency of hemorrhage in SBI,
pointing to a favorable profile of unwanted side
effects. In general, anticoagulatory therapy carries
an increased risk of bleeding, and this would
reduce enthusiasm for a therapy targeting SBI,
which is not a life-threatening condition. How-
ever, this was not the case for rHA-Infestin-4.
This finding is in line with the symptoms of
hereditary FXII deficiency, which do not include
inadequate bleeding. Altogether, the data suggest
that FXII inhibition could serve as prophylactic
therapy in high-risk cases and may be safe in
patients who undergo procedures involving arte-
rial catheterization or vascular surgery. These
hypotheses will have to be tested in future stud-
ies, especially because therapy was started 1 h
after embolization in our study.
Study limitations. Limitations of the model include
he observed microhemorrhages, which have not
een reported in clinical cases of SBI. Future
tudies should also focus on long-term sequelae and
xplore whether these are comparable to the clinical
Figure 8. MRI of MPO Activity on Day 3 After Microbead-Induce
Assessment of MPO activity 3 days after SBI after microbead em
FRI shows position of beads. MPO-positive volume is normalizedC O N C L U S I O N S
Our findings in mice demonstrate that in SBI,
both coagulation and inflammatory pathways are
activated, regardless of whether the cause is a
migrating thromboembolus or other material.
The coagulation abnormality and, more impor-
tant, the amount of ischemic injury resulting
from microembolism were effectively reduced by
factor XIIa inhibition, pointing to a novel treat-
ment option to decrease the morbidity of SBI.
The molecular imaging technologies used here
allowed not only a better understanding of the
biology of SBI, but may also have translational
value to determine the severity of SBI in patients.
The study further indicates that these molecular
imaging strategies could be a sensitive tool to
monitor therapeutic efficiency.
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